05:32 PM EDT, 03/19/2024 (MT Newswires) -- Corvus Pharmaceuticals ( CRVS ) said Tuesday it expects to start a phase 1 study of soquelitinib in patients with moderate to severe atopic dermatitis in Q2.

Corvus expects to enroll 64 patients who have previously failed at least one therapy and compare four different doses of the drug with placebo for safety and disease severity in the 28-day trial.

An initial readout of the trial is possible before the year's end, according to the company.

The company shares were down 1.5% in recent after-hours activity.

Price: 1.93, Change: -0.03, Percent Change: -1.53